X-ELIO, a global leader in the renewable energy sector, and the Net Zero Consortium for Buyers (NZCB) have announced the signing of six virtual power purchase agreements (PPAs) for a combined total ...
global head of Biogen’s biosimilars unit. “With the increasing numbers of approved biosimilars, we expect increased savings and sustainability for healthcare systems and an increase in ...
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Biogen receives exclusive rights to commercialize ... Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels ...
Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the ...
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results